LENZ Therapeutics, the Solana Beach, Calif., company that sells the presbyopia eye drop VIZZ, will shrink its workforce by about three-quarters, leaving approximately 40 full-time employees, according to a Form 8-K filed with the Securities and Exchange Commission on Wednesday, Oct. 28.
Molecular Partners AG, a clinical-stage biotech company listed in Zurich and on Nasdaq, said Thursday, Oct. 29, that it intends to cut no more than 55 positions, or up to about 44% of its workforce, as it concentrates on radiopharmaceutical cancer drugs.
Fractyl Health, a Burlington, Massachusetts, developer of obesity and type 2 diabetes treatments, will cut about 45% of its workforce as it concentrates its money and staff on a single product candidate, the company said in a securities filing and a press release on Thursday, Oct. 22.
EyePoint, a Watertown, Massachusetts, drug developer focused on retinal diseases, plans to cut about 53% of its workforce after a pivotal trial of its lead drug candidate in wet age-related macular degeneration missed its primary goal. The company announced the plan Monday, Oct.
